Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab
Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab is a paper indexed in PICO Portal from OpenAlex.
How many citations does Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab have?
Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab has 364 citations in the OpenAlex counts PICO Portal stores.
When was Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab published?
Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab has 2005 year in the PICO Portal index.
What is the open-access status of Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab?
Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab has closed oa status in the PICO Portal index.
What is the DOI of Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab?
The DOI for Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab is on the source record.
What is the PMID of Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab?
The PMID for Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab is on the source record.
What is the OpenAlex record for Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab?
The OpenAlex for Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab is on the source record.